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2Abstract
Transdermal administration offers a non-invasive and convenient method for paediatric
drug delivery. The competent skin barrier function in term infants and older children limits
both water loss and the percutaneous entry of chemicals including drugs; but the smaller
doses required by children eases the attainment of therapeutic concentrations. Transdermal
patches used in paediatrics include fentanyl, buprenorphine, clonidine, scopolamine,
methylphenidate, oestrogens, nicotine and tulobuterol.  Some patches have paediatric
labelling supported by clinical trials whereas others are used unlicensed. Innovative drug
delivery methods, such as microneedles and sonophoresis are being tested for their safety
and efficacy; needleless injectors are primarily used to administer growth hormone; and two
iontophoretic devices were approved for paediatrics. In contrast, the immature and rapidly
evolving skin barrier function in premature neonates represents a significant formulation
challenge. Unfortunately, this population group suffers from an absence of approved
transdermal formulations, a shortcoming exacerbated by the significant risk of excessive
drug exposure via the incompletely formed skin barrier.
Keywords: transdermal drug delivery, transdermal patches, paediatric dosage forms,
premature neonates, iontophoresis, skin, stratum corneum.
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41. Introduction
The topical and transdermal routes of administration offer some clear and specific
advantages for drug delivery. Topical delivery allows targeting of the drug to the local area
minimizing systemic exposure; topical formulations usually contain anti-inflammatory, anti-
histaminic, antifungal, antiseptic, and analgesic drugs incorporated into creams, ointments,
gels, sprays and, less frequently, patches. Transdermal drug delivery (TDD), the object of this
review, aims to provide effective systemic concentrations for central, rather than, local
effect and is applicable to different therapeutic areas. TDD offers a non-invasive approach to
avoid the first-pass effect, and can sustain plasma levels within the therapeutic window for
extended periods. Transdermal patches are usually well accepted, easy to apply and
represent a valuable alternative when oral administration is difficult (e.g., patient cannot
swallow, or is in a coma) or may result in erratic absorption (nausea, vomiting, etc.) [1].
While these advantages are of general interest for the paediatric population, neonates and
preterm infants would benefit particularly from a non-invasive route of drug administration
and an alternative to oral and intravenous delivery [2]. Unfortunately, the effective barrier
properties of the skin mean that TDD is not suitable for all drugs and only those with
appropriate physicochemical, pharmacokinetic and pharmacodynamics properties are
candidates for delivery across the skin [1, 3]. All drugs available in commercial, passive
patches are highly potent, have molecular weights less than 500 Da, and log P
(P=octanol/water partition coefficient) values typically between 3-5 [3]. While newer
delivery methods such as iontophoresis, needleless injectors and microneedles expand the
range of drugs administrable, by easing the constraints related to drug polarity, charge and
size, the doses deliverable across the skin remain small. Conveniently, because younger
children require smaller doses than adults, it is conceivable that some drugs could be
delivered transdermally for paediatric but not for adult use.
Human skin is responsible for several functions including photoprotection,
thermoregulation, hormonal synthesis, sensory perception, and immune and barrier
functions [4, 5]. Among these, barrier function is the most relevant to drug absorption and
not surprisingly, many enhancement techniques have been examined to overcome this
challenge [1, 6]. Nevertheless, it is important that the normal functioning of this organ is not
disrupted severely because of its key role in survival. The majority of techniques developed
5to enhance skin transport have been tested in adult human skin or in animal models [1, 6]. A
key question, therefore, is the extent to which “paediatric skin” is represented by these
models and whether the knowledge obtained from these models can be transferred and
exploited for the benefit of the paediatric population. Importantly, while the latter
represents a heterogeneous group of individuals; from the standpoint of the skin barrier
function and transdermal absorption, it divides (to all intents and purposes) in two large
parts: (1) all children, including neonates born at full-term, whose skin is functionally
indistinguishable from adult skin, and (2) preterm neonates who have a thinner and
dysfunctional epidermal barrier.
A premature neonate born at ~ 25 weeks gestational age (GA) with very low weight (<0.75
kg) has a very fragile skin which can easily tear; infants born at 30-31 weeks GA and
weighing 0.75-1.25 kg have a more resilient, although still immature, skin; finally, the skin of
infants born from ~36 weeks GA (1.2-2.0 kg) will be almost as tough and functional as that
of full-term new-borns [4]. Premature neonates are obviously the most challenging group
concerning transdermal drug administration. Despite significant progress, the relationship
between skin absorption, GA and post-natal age (PNA) in this population is insufficiently
characterized, making it difficult, if not impossible, to modify drug input in response to not
only the rapidly evolving skin barrier function but also to the drug dose requirements (which
also increase with PNA); in addition the situation is likely to be further complicated by other
underlying developmental and disease issues. Information about the criteria for formulation
selection is also missing; for example, whether a patch adhesive is suitable for fragile
premature skin, or the potential risk associated with the unexpectedly high absorption of an
excipient. While the remarkable immaturity and poor barrier function of pre-term infant
skin is universally recognized, there has been debate about the point at which the skin of
term infants gains adult functionality. The next section summarizes the key issues and deals
more specifically with the development of the skin barrier function.
Importantly, while permeation across the stratum corneum (SC) or outermost layer of the
skin, constitutes the rate-limiting step for the skin absorption for most chemicals, the overall
absorption process can be modified by other factors not related to the skin barrier
maturation (including occlusion, thickness of applied formulation, area of application versus
body surface area); furthermore, drug response and toxicity are also determined by
6pharmacokinetics and pharmacodynamics which change within the paediatric population
and may be quite different from those in adults. To illustrate this point, the skin represents
~13% of the body weight of a pre-term infant but only 3% of that of an adult [7]; the area
and site of application of a transdermal patch may have a dramatic impact, therefore, on
the safety and efficacy of a treatment in neonates [2, 8].
2. The development of skin barrier function.
The differences between infant and adult skin physiology, as well as the development of
skin functionality, including the effects of GA and PNA on transepidermal water loss (TEWL),
skin surface pH, skin hydration, skin electrical properties, skin structure and roughness and
natural moisturizing factor (NMF) abundance, have been recently and extensively reviewed
[5, 7, 9-10].
The development of skin structure from the embryo until birth was comprehensively
reviewed by Hardman et al., [10]. Briefly, at 4-5 wk GA the ectoderm of the embryo is
covered by the periderm; epidermal stratification starts around 8 wk GA, and the
development of skin appendages around 12 wk GA [4, 5]. The periderm acts as the interface
between the amniotic fluid with the developing epidermis prior to SC formation; later the
periderm sheds to become part of the vernix caseosa at 15-20 wk GA. The effects of GA and
PNA on the histological development of the epidermis were reported in 169 (24-40 wk GA)
infants aged from a few hours to 1 year old [11]. The thickness and number of epidermal cell
layers, the degree of undulation of the dermo-epidermal junction, and the SC thickness
increased clearly with GA in children who had died within 7 days of birth; both the SC and
the dermo-epidermal undulations were barely perceptible until 34 wk GA. It was suggested
later that, while functional maturation of the SC starts around the 24 week of gestation, a
well-defined SC is not visible before 34 wk GA. Indeed, SC formation has been observed at
22 wk GA in the epidermis of the head/scalp and in palmar/plantar skin and, at 25 wk, over
the rest of the body [12]. According to some, a functional skin barrier appears regionally,
with the inter-follicular barrier forming at 20-21 wk GA on the head and at 23-24 wk GA on
the abdomen. The barrier appears to develop between 20-24 wk GA in a patterned manner,
starting at specific initiation sites but also around emerging hair follicles. The link between
epidermal differentiation and skin permeability during foetal development was
7characterized for 55, 75, 84, and 96 d GA and 115 d (full-term) swine foetuses [13]; the
permeability to arecoline decreased significantly for the 96 d GA group corresponding to the
visual appearance of the SC and the partially keratinized epidermis. Notably, the
permeability of ionized arecoline across skin from 96 d GA and older foetuses was
significantly less than that of the unionized species, an observation consistent with the
development of a lipid barrier.
It is now generally accepted that the inward percutaneous penetration of chemicals is
correlated to the transepidermal water loss (TEWL) [14]. Further, the link appears to be
maintained throughout the human-life span. The topical absorption of hydrocortisone in a
group of 3 children and 6 adults (3 to 52 years) with widespread dermatitis produced a
significant correlation between TEWL and the post-application plasma levels of cortisol
irrespective of age [15]. It is therefore not surprising, that TEWL has been extensively used
both to characterize the degree of skin barrier function and maturity and to predict
chemical absorption.
The earliest studies of insensible water loss (IWL) aimed to develop adequate support for
pre-term neonates, in particular, to maintain fluid balance and to determine the effect of
different care techniques on water loss. Weight loss was used as an indirect measurement
of IWL accounting therefore for both water loss through the skin areas and via respiration
[16] (although, according to some [17], IWL accounts for ~90% of the weight loss). As early
as 1972, it was hypothesized that immature skin was the reason for the high IWL observed
in a cohort of 30 infants of 23-36 wk GA [17]. Because IWL is modified by additional factors
such as basal metabolic rate, ambient and body temperature, relative humidity, neonate
activity, and phototherapy, the results from different studies must be carefully compared
[18]. In fact, important effects of radiant therapy, incubators, bililights and radiant heaters
on IWL (weight loss) and TEWL have been demonstrated [19-20]. However, despite these
additional contributing factors, a clear inverse relationship between body weight and IWL
(weight loss) was reported for 54 healthy pre-term infants [21]; additionally, it was shown
that IWL decreased with PNA for infants with birth weights of ≤1.5 kg, a correlation
interpreted as a sign of skin function maturation. One of the earliest explicit links between
skin barrier function development and TEWL was a study in 28 infants of 2-9 d PNA and 26-
41 wk GA [20]. TEWL was significantly higher for premature infants born at 27-29 weeks GA;
8it was also observed that older preterm and normal term infants had similar TEWL, which
again suggested fast, post-natal skin maturation for the pre-term group.
Significant progress was then possible due to the development of “evaporimeters” that
directly measured water vapour at the skin surface, and numerous investigations with this
apparatus then confirmed previous findings [22-23]. TEWL (evaporimeter) was inversely and
exponentially related to GA for both low and normal weight infants during the first 4 weeks
after birth [24]. Even when directly measured at the skin surface, the TEWL in term and pre-
term infants can be modified by multiple factors including body temperature, ambient
humidity, physical activity, maturity, nutritional status at birth, cold stimulation, GA and
PNA; the contributing factors can be changes in skin structure, sweat gland function and
activation, skin blood flow, skin hydration, basal metabolic rate, and total body water [16,
23]. The use of radiant warmers approximately doubles IWL (measured as weight loss) of
infants [18]; the use of heat shields reduces this effect [25]. Administration of prenatal
steroids (to the pregnant mother) does not affect foetal barrier maturation; in contrast
post-natal parenteral steroid administration inhibits this process [26].
The key findings of the initial measurements of TEWL using evaporimeters have been
summarized [27]. It is worth noting that some work involved determination of TEWL at a
specific site on the body, while others average measurements made at (e.g.,) three locations
to inform total fluid loss [27]. Clearly, in terms of using TEWL as a marker of skin
permeability in general (including to drugs), the individual assessments at specific skin sites
are more useful.
The effect of GA on percutaneous absorption in preterm infants was nicely demonstrated by
a method to assess skin permeability based on the blanching response observed following
topical application of Neo-Synephrine® aqueous solution [28]. The blanching effect was
visible in all 28-34 wk GA infants but was lost beyond 21 d PNA; the response was delayed
and of lesser magnitude in infants born at 35-37 wk GA; and there was no blanching effect
in infants born at 38-42 wk GA. A further study linked TEWL with drug absorption in 70 new-
borns classified in four GA groups (Fig.1) [29]. The vasoconstriction observed after topical
application of phenylephrine was minimal for infants of ≥37 wk GA who also showed the
lowest TEWL (< 10 g.h-1.m-2); infants born at 33-36 wk GA, with a TEWL slightly higher than
9the previous group, showed a mild response which became less marked after ~1 wk PNA
(and corresponded with a drop in TEWL); a higher TEWL and an increased response to
phenylephrine was observed for infants of 30-32 wk GA and, in this case, TEWL fell to
normal values and the response disappeared by 2 wk PNA; finally the most immature infants
(<30 wk GA) showed the largest blanching response and the highest TEWL which again
decreased to normal two weeks after birth [29]. Thus, a striking correlation between
blanching effect, a surrogate marker for drug absorption, and TEWL was observed. Parallel
measurements found an increased blanching response in skin sites with increased TEWL
caused by barrier perturbation upon removal of adhesive tapes and medical rings. The
transdermal absorption of benzoic acid was elevated in pre-term infants and declined over
three weeks to “normal” levels based on results in adults [30]. The rapid changes in TEWL
and chemical absorption observed post-natally in pre-term infants are consistent with the
histological changes previously reported [11]. For example, the skin of infants born at 24-30
wk GA shows a significant increase in the number of epidermal cell layers and develops a
well-formed SC over a 16 week post-natal period; however, little development of dermo-
epidermal undulations was observed.
By the end of the 1980s, the emerging message was that TEWL and percutaneous
absorption across the skin of full-term neonates were similar to those in adults, while
premature infants (less than 34 wk GA) had an incomplete skin barrier and were vulnerable
to dehydration and infection, and to the dermal uptake of potentially toxic substances. An
alternative point of view was that premature skin offered an accessible and non-invasive
route of drug delivery for this population, enabling the facile administration of therapeutic
doses. However, the rapid, functional development of premature infant skin (often evolving
to a mature barrier after ~2 wk PNA) confounds this potential drug delivery opportunity:
how does one develop methods to predict the level of skin maturity and permeability for a
specific new-born, and then design formulations, which can safely deliver drugs with the
required rate and extent of absorption to this rapidly evolving “moving target”?
The current advances in postnatal care make it possible for ultra-low birth infants to survive.
Skin barrier development was assessed in 23-32 wk GA children using TEWL and impedance
spectroscopy [26]. Low-frequency skin impedance increased significantly with barrier
development and was inversely correlated with TEWL; i.e., TEWL was highest (60-70 g.h-1.m-
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2) and low frequency impedance smallest for infants born with the shortest GA and PNA.
Barrier function development appeared to accelerate at 200-220 days post-conception,
regardless of GA and PNA, and 30 wk GA was identified as a key milestone. Significantly, the
very premature infants had not achieved a competent barrier 2-4 weeks after birth;
furthermore, in some subjects, a detrimental effect of parenteral steroid administration on
barrier function development was observed.
An interesting feature of new-born skin is the vernix caseosa, a film of lipoproteic material
with embedded foetal corneocytes that is missing in infants born at less than 28 wk GA [31].
The vernix caseosa is composed of water (80.5%), proteins (8-10%) and lipids (8-10%);
cholesterol is the major lipid component followed by free fatty acids (FFA) and ceramides. In
contrast, FFA represent the dominant lipid in both post- and pre-natal skin [32]. It is
estimated that ~30% of the lipids of the vernix caseosa originate from the epidermis with
the remainder coming from sebaceous glands. It has been suggested that the vernix caseosa
is shed when the transepidermal lipid barrier is sufficiently developed; hence, its
disappearance is used as a mark of foetal maturity [33].
To summarize, it is clear that the SC of pre-term new-borns provides a defective barrier
resulting in significantly elevated TEWL. On the other hand, the SC of term neonates
provides a competent barrier with TEWL similar to that across adult skin [5]. The
competence of the full-term infant skin is supported by considerable research, some as early
as 1977 [34] which showed that TEWL and carbon dioxide emission rates across the skin of
healthy term infants and healthy adults were comparable.
Differences as a function of body site have also been considered. TEWL  was comparable
across abdominal, buttock and forearm skin of 13 (8-48 h PNA) new-born term infants and
was significantly increased after 1 hour occlusion at the three sites A study on 28 (38-40 wk
GA) healthy infants examined 18 body sites and found significant inter-site variability; TEWL
was particularly high on the forehead and palm of the hand, elevated on the cheek, upper
arm, and sole of the foot, and lower on the abdomen and chest [35]. It is possible that
environmental factors (relative humidity, occlusion, effect of diapers) contributed to some
of the differences observed.
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Recently, an investigation in 1,036 healthy term infants provided the most comprehensive,
reference values for TEWL on the arm measured with an open-chamber evaporimeter [36].
The results were normally distributed with a mean (± standard deviation) of 7.06 ± 3.41 g.h-
1.cm-2, comparable to that of adult skin. The results for 18 late pre-term infants (34-37 wk
GA) was rather similar: 7.76 ± 2.85 g.h-1.cm-2. It should be noted that open- and closed
chamber evaporimeters provide different absolute TEWL readings [37-38], preventing a
direct comparison between results obtained with the two approaches; unfortunately, a
comparative reference data set is not available for measurements made with a closed
chamber evaporimeter.
The link between skin lipids and barrier function has been considered. In 1978 [39], TEWL
(resistance hydrometry) and the concentration of skin surface lipids were measured in 40 (3-
12 y) healthy Japanese children. TEWL was not modified by age, gender, and weight; on the
forearm the values in children (0.23 ± 0.03 mg.cm-2.h-1) and adults (0.24 ± 0.02 mg.cm-2.h-1)
were indistinguishable. Similarly, the amounts of cholesterol on the children’s skin (2.84 ±
1.74 µg.cm-2) and on adult skin (2.44 ± 1.44 µg.cm-2) were not statistically different;
however, the children’s skin had significantly less squalene (0.31 ± 0.25 µg.cm-2) than that of
adults (0.74 ± 0.61 µg.cm-2). The difference in sebaceous lipids, which are not considered as
key contributors to barrier function, was explained by the immature secretory activity of the
sebaceous glands in children. On the other hand, a clear relationship between the
concentration of non-sebaceous lipids and TEWL was observed. Later work found significant
differences in the composition of lipids extracted from the epidermis at 14-17 wk and at 20-
28 wk GA; the latter group also had less lipids than typically found in adults [40].
While TEWL is essentially the same in adults and full-term infants, other aspects of skin
function do change after birth. These differences between infant and adult skin physiology
have been reviewed [5, 7, 9] and concern properties such as skin surface pH, skin hydration,
skin and SC thickness, desquamation and corneocyte size. Some of these results are based
on data from small cohorts and may be difficult to generalise due to differences in
methodology and skin sites studied (see [7] for comprehensive details). A comparison
between 70 (8-24 months old) children and 30 (25-35 y) healthy women revealed, as
expected, that baseline TEWL was the same in both groups; however, skin capacitance
(measured with a corneometer) was higher on the volar forearm of children (but not on the
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buttocks) than that of adults, and that skin pH was higher in children (5.5 - 5.8) than in
adults (4.5 – 5.0) [41]. In healthy, full-term neonates, a decrease (0.3 - 1.1) in surface skin
pH, increased desquamation on the face, a smoother skin surface, and an increase in SC
hydration were noted during the first 3 months of life [42]. Another investigation also
recorded that the skin surface pH fell from neutral to 5.0 - 5.5 within two weeks of birth.
TEWL (evaporimeter), skin hydration (corneometer), skin surface pH, and the Raman
confocal microscopy (RCM) profiles of water and natural moisturizing factor (NMF) were
assessed in  children (1 d - 5 y) and adults [43]. TEWL was similar as expected, while skin
surface pH decreased from ~6.0 for new-borns to 5.10 by 5-6 wk, 5.20 at 4-5 y, and to 5.5 in
adults (20-35 y). The average area-under-the curve of Raman-assessed NMF levels as a
function of skin depth was greatest for new-borns and smallest for the 6 month age group;
however, mean AUCs for lactic acid were similar for all ages. Finally, skin capacitance was
lowest at birth and highest for the 5-6 wk and 6 m age groups. RCM was also used to show
that the skin of infants (3-12 m) has less NMF but a higher water content than adult skin; it
should be pointed out that this is one of the few studies to report higher (4-5 fold) TEWL
values for 3-12 m children than for adults [44]. According to Hori et al., [45] the skin
developmental process over the first year of life differed in the upper thighs with respect to
that observed in diaper-covered areas.
It was reported that 36-40 wk GA infants experience an increase in epidermal cell number,
and epidermal (but not SC) thickness, and developed a more undulated dermo-epidermal
junction from birth until 16 wk PNA [11]. Elsewhere, infant skin has been shown to have
smaller corneocytes, faster cell turnover and a thinner SC than adult skin [9]. The latter
finding, in contradiction to previous work, may be an artefact of the methodology used
which assessed SC thickness from optical sections taken every 3.1 µm, which is close to the
difference reported between adult (10.5 ± 2.1 µm) and children’s (7.3 ± 1.1 µm) SC thickness
[9]. Skin equivalents (SE) from new-born, child and adult foreskin keratinocytes were
produced and compared; briefly, those from new-borns had a greater proportion of stem
cells (as indicated by K19 expression) and produced a thicker skin (than the adult cells) more
quickly. However, once keratinocyte differentiation was induced, the three mature SEs were
similar in their histological expression of differentiation markers and in lipid content.
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Further, transport of hydrocortisone across SE samples was similar for the three groups,
although higher than across foreskin samples [46].
Nevertheless, of all skin physiological properties and their possible development through
infancy [7], none has been linked to the percutaneous absorption of chemicals as
unquestionably as TEWL. An additional factor, of potential relevance to skin barrier
function, is cutaneous blood flow. At birth, capillary loops are only seen in the nails bed,
palms and soles, and are not observable in all skin sites until 14-17 wk; furthermore, the
development of the cutaneous micro-vasculature is site-dependent [5]. It is believed that
adaptation of the dermal microcirculation can take longer in preterm infants, but how
exactly that may translate into altered skin absorption has not been deconvolved. This is a
complex issue as skin blood flow is modified by ambient temperature, relative humidity and
nutrition.
The SC structure and composition, especially that of the intercellular lipids, govern TEWL
and play a major role in determining the rate and extent of skin absorption across this
barrier [47]. Together with the physicochemical properties of the permeant, SC
development defines, therefore, the feasibility of passive topical/transdermal drug delivery
and the risks associated with dermal exposure via passive diffusion. On the other hand, the
skin appendages (sweat glands, hair follicles) represent important permeation pathways for
some alternative delivery approaches, such as iontophoresis [48]. The development of hair
in utero and in neonates has been characterized and it has been suggested that an infant is
born with a fixed number of sweat glands and hair follicles meaning that the number of
annexes per unit area of skin decreases with growth [49]. For example, the follicular density
on the scalp of new-born infants has been reported to range from 500 to over 1100 per cm2;
in contrast, in adults, the corresponding values on the occipital scalp have been measured to
be only 239 and 292-455 per cm2 [49-51]. The hair follicle density in adults is significantly
lower (14-90 follicles.cm-2) at other body sites, but comparable values are not available for
new-borns [50]. More recently, video-dermatoscopy was used to characterize five areas of
the scalp in 45 neonates, and identified that two clinical patterns, namely “good hair
density” (GHD) and “poor hair density” (PHD) can be present at birth. These groups could be
separated by cut-off values for hair density (505 hair.cm-2), hair shaft diameter (0.06 mm),
and hair length (2 cm). PHD neonates typically had lower birth weight with ~20% of new-
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borns showing widespread thin hair (0.04 mm diameter and 2 cm length) [49]. However,
despite the potential impact of these observations on skin permeation, the role of hair
density at different body sites in different paediatric groups remains completely
uncharacterized.
Likewise, little is known about the importance of other skin annexes on barrier function.
Thermoregulation and eccrine gland function does not mature until after term [5, 7, 31]. At
24-29 wk GA it is possible to observe sweat glands with an adult structure, complete with
secretory ducts. The appearance and cellular differentiation of the eccrine system is the
same in term and pre-term infants; however most >36 weeks GA infants can sweat in
response to environmental stimulus on their first day of life whereas pre-term (< 36 weeks
GA) cannot [5, 7]. Transdermal electrical potential measurements also suggest that sweat
glands are immature in infants of less than 24 wk GA, skin resistance increases with GA and
appears to mature around 36 weeks GA [52]. Sebaceous glands, which provide most of the
lipids for the vernix caseosa, are visible by the 18th week of gestation but remain
hypertrophic for some weeks after birth as a result of maternal hormone exposure [5, 7,
10].
3. Skin absorption: potential for toxicity and for transdermal drug delivery in paediatrics.
3.1 In vitro and in vivo skin drug absorption studies.
The transdermal delivery of xanthines (theophylline and caffeine) to treat apnoea in
premature infants was one of the earliest applications taking advantage of the increased
skin permeability in this population. Transdermal administration was considered
advantageous and convenient, removing the need for an IV line and avoiding fluid overload,
and preventing reduced gut motility and bacterial overgrowth associated with oral
administration [53-54]. Evans et al. [55] delivered theophylline sodium glycinate from a 15%
w/w gel to 20 infants (26-30 wk GA; 1-20 d PNA; 0.6-1.44 kg weight). Therapeutic drug levels
were reached within 9-30 h in children naïve to theophylline. Furthermore, the gels were
able to maintain effective drug concentrations in infants who had, up to that point, been
receiving an aminophylline infusion. In a similar fashion, the drug was formulated in
hydrogel disks and plasma concentrations of theophylline in the therapeutic range were
attained and maintained for up to 15 days in 18 (24-30 wk GA) preterm infants [56]. An
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inverse correlation was observed between the maximum concentration observed and TEWL;
for example, a child with very immature skin and extremely high TEWL (100 g.m-2.h-1)
developed signs of theophylline toxicity. The pharmacokinetics of theophylline after
transdermal administration were investigated in 9 (32-36 wk GA) infants [53]. The mean
half-life of the drug as 28.7±6.1 h; however, sub-therapeutic levels of theophylline were
attained in this group of older infants. The administration of caffeine monohydrate (18 mg.g-
1 caffeine base) from an aqueous gel produced good efficacy and was well tolerated in 18
premature (<32 weeks GA) neonates [57]. It was suggested that caffeine treatment would
normally no longer be needed by the time that skin barrier function had developed
sufficiently thereby limiting the percutaneous absorption of the drug. In another
investigation, a caffeine citrate gel was administered to 57 premature (<34 wk GA) infants
and resulted in therapeutic levels in 73% of the patients after ~48 h and in 97% within 5
days of treatment [54]. High, but asymptomatic levels were observed in 5 subjects at 48 h,
and in 19 infants at 6 days; sub-therapeutic levels were detected in 12 neonates at 48 h.
Overall, a significant decrease in the frequency of apnoea episodes was observed [54].
Similarly, the application of a different caffeine gel to 56 preterm (26-34 wk GA) infants
produced systemic levels which increased from day 2 to day 10 of treatment, reaching
therapeutic efficacy in 48 h [58]. Serum concentrations were better correlated to
gestational age than birth weight; high drug levels, although without side effects, were
measured for the most immature patients. Nonetheless, despite these early, promising
results, neither a theophylline nor a caffeine formulation has been developed for this
population; in fact, only the oral and parenteral routes are routinely listed in reference
guidelines for the treatment of infant apnoea [59-60].
Although the topical administration of glyceryl trinitrate (GTN) to induce vasodilatation in
children and to facilitate access to peripheral veins has been reported [61], a subsequent
double-blind study in 23 infants (3 wk-10 y) found the approach inefficient and
demonstrated no relation between local drug concentration and venous distension [62].
Case reports have described the effective use of a topical GTN ointment to treat (a)
perniosis in a 6 m old boy, who was unresponsive to other therapy [63] and (b) severe tissue
ischemia in four neonates [64], but neither publication has provoked any further activity in
this area.
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As drug dose requirements in children are typically lower than those in adults, the
transdermal route of administration may be more feasible in paediatric subjects [59,65].
Nevertheless, some targets remain unrealistic. For example the daily, neonatal dose range
for paracetamol is 10-30 mg.kg-1 [59,66], which cannot be achieved across the skin. Even
when the target delivery rate is more reasonable, careful consideration of the formulation
(and, in particular, the use of penetration enhancers) is necessary to minimise the potential
for skin irritation. This raises the important question as to how the feasibility of transdermal
drug administration in infants may be assessed pre-clinically? Clearly, in vitro permeation
experiments using adult human skin are possible, but the better barrier function (relative to
premature neonate skin) may lead to an erroneous conclusion. Likewise, there is little
evidence to support the use of an animal model (even those with known higher skin
permeabilities than man) as the relative permeability with respect to infant skin is not
known. Ideally, the best in vitro model would be neonatal skin, but the availability and
procurement of such tissues pose real problems for obvious reasons. However, there have
been some reports describing drug transport measurements across skin samples obtained
from infants post-mortem. For example, the in vitro skin permeation of phenobarbital,
which is used to treat status epilepticus, neonatal seizures, and neonatal abstinence
syndrome, has been investigated [67]. Unsurprisingly, drug flux was higher across skin
sourced from the most immature infants. Phenobarbital penetration decreased with
increasing GA and, from 37 weeks, it was very similar to that across adult skin (Fig.2-3).
While it was suggested, on the basis of the results obtained that a therapeutic dose could be
delivered transdermally to pre-term and term neonates, the formulation used (39 µL.cm-2 of
a 2 mg.mL-1 of phenobarbital in ethanol) was obviously sub-optimal.
The in vitro delivery of the analgesic diamorphine across skin from premature neonates also
showed a clear inverse relationship with the donor GA (Fig.2) [68]. Despite the simplicity of
the formulation, it was concluded that a 2 cm2 patch could be of therapeutic use. It was
noted that the time required to attain the steady state would be greater for paediatric
patients for whom drug elimination pathways are still immature. While the authors of this
work suggested that this problem could be solved with an IV loading dose, the current state-
of-the-art suggests that iontophoresis can achieve the same objective and render the entire
therapy completely non-invasive.
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The increased skin permeability of the preterm population also offers an opportunity for
non-invasive sampling [69]. An initial investigation involved the transcutaneous collection of
theophylline and caffeine in 33 (25-34 wk GA; 2-89 d PNA) infants on theophylline therapy
[70]. The 2.54 cm2 collection systems were composed of 3% agarose, 5% activated charcoal
and a 92% salt solution, and were applied for either 4 or 12 hours. Both drugs were
detected in the patches but, while the outward fluxes were related to the corresponding
plasma levels and post-conception age, they were poor predictors of individual
concentrations. The potential of iontophoresis [71] to improve transdermal sampling was
later tested and, in this case, tape-stripped pig skin was used as an in vitro model for
premature skin (see below). Iontophoresis increased and significantly accelerated extraction
of caffeine and theophylline compared to passive diffusion across intact skin but showed
little benefit when the SC was absent. Unfortunately, the drug extraction flux as a function
of its subdermal concentration across skin with intermediate barrier function was not
reported.
3.2 Unwanted skin absorption and potential for toxicity.
Concerns about the undesirable systemic absorption of actives and excipients have focused
primarily on antiseptics and other topical treatments routinely applied to new-born and,
more particularly, preterm infants. The risk of systemic exposure has to be carefully
balanced against the need for effective skin disinfection, which is essential to reduce the
incidence of infections in new-borns, especially in premature infants who are often
subjected to multiple invasive procedures. The potential for undesirable chemical skin
absorption in neonates is historically illustrated by hexachlorophene, an antibacterial that
was later withdrawn due to safety concerns [72]. Similarly, topical iodine-based
disinfectants have also been withdrawn [73]. For example, their use was associated with
hypothyroidism in 4 infants (average 37 wk GA) with spina bifida, a side-effect attributed to
excessive iodine absorption from antiseptic dressings (povidone iodine 10%) [74]; another
study in 30 (26-30 wk GA) infants found increased levels of urinary iodine and some effects
on thyroid function [75]. A recent systematic review [76] concluded that topical exposure of
preterm infants to iodine (<32 wk GA) leads to thyroid dysfunction. Similarly, the use of
alcohol-based products in pre-term infants can cause serious harm as illustrated by the case
of a 27 wk GA whose skin was cleaned with methylated spirits (95% ethanol; 5% wood nafta
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which contains a minimum 60% methanol); post-mortem blood samples (18 h after
exposure) revealed concentrations of ethanol and methanol of 2.59 mg.mL-1 and 0.26
mg.mL-1, respectively [77].
Chlorhexidine (CHD) was subsequently proposed as a safer alternative for antisepsis in the
neonate population as it was, apparently, less well absorbed through intact human skin [78].
Initial research was conducted in rhesus neonates bathed daily for 13 weeks with a skin
cleanser solution containing 8% chlorhexidine gluconate (CHG), twice the concentration
routinely used at that time [79]. Blood and tissue levels indicated that little systemic
absorption had occurred, with only one blood sample having the minimum detectable
concentration (11 ng.mL-1) at the time. Heel prick and venipuncture were then used to
assess the potential systemic exposure to CHG in 34 (28-39 wk GA) newborn infants [80].
While heel prick measurements were all positive, this was explained by residual
chlorhexidine in the skin not removed by an alcohol wipe. Venous samples taken 4 h after
bathing were 101-460 ng.mL-1 in 3 of 7 infants, but only 5% of the samples taken 12 h after
the bath were positive. In this study, Hibiscrub (4% CHG in a detergent solution) was used
for the daily bath and some of the infants were already a week PNA when the trial began.
Further work confirmed the potential absorption of CHD in neonates, particularly in the
preterm population, and illustrated the key role of the formulation used [81]. Infants
treated with 1% CHD in ethanol had increased plasma levels, whereas the antiseptic was not
found in those bathed with 1% CHD and 3% zinc oxide dusting powder. Similarly, when 4%
CHG diluted 1:10 was used to bathe full-term infants, no detectable plasma levels (LoD=0.1
µg/mL) were found (although, in this case, the head, a significant surface of a neonate, was
not bathed) [82]. In contrast, first- and second-degree chemical burns developed in two
twins (26 wk GA) treated with 0.5% CHD in methanol despite the immediate washing of the
skin with saline [83]. In fact, alcoholic preparations of CHD are not recommended for
neonatal care. Elsewhere, it was reported that 10 of 20 neonates (24-31 wk GA), who were
treated with 2% aqueous CHG prior to catheter insertion, had detectable plasma levels (1.6-
206 ng.mL-1) of the compound, and the highest concentration was observed 2-3 days after
exposure [84]. Overall, while the evidence suggests that CHG can be absorbed across the
skin of preterm and term infants of less than 2 months of age, the clinical significance of the
exposure is unknown [78]. Most of the reported adverse effects are local, such as erythema
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and contact dermatitis. Concerning skin burns, the results from different formulations and
the effect of alcohol should be clearly discriminated. Other factors determining
accumulation are the area of application considered (whole body bath or umbilical cord
application) and the exposure frequency. The safety of CHG in preterm infants has been
recently reviewed [78] and further investigated [78, 84] given that the FDA has now
approved a labelling change which allows the cautious use of CHG products in preterm
infants [84].
Propylene glycol (PG) is an excipient commonly found in topical preparations. High plasma
and urinary excretion levels have been reported in premature infants primarily from
dressings used to treat burns [85]. PG accumulation may result in toxicity such as serum
hyper-osmolarity and lactic acidosis [86-87] and, while the parenteral route is typically
associated with a larger exposure [88], there have been cases associated with topical
application to compromised skin [86]. The WHO has set an acceptable daily limit of PG
intake of 25 mg.kg-1 for adults [88]. Despite the longer elimination half-life in neonates [87]
that could result in greater accumulation, a median PG exposure of 34.1 mg.kg-1.day-1 did
not affect postnatal renal, metabolic and hepatic adaptation in 60 neonates who were
exposed to PG as an excipient as part of their routine therapy [89]. There is little
information about the safety of PG in topical and transdermal formulations applied to intact
skin.
The undesired systemic absorption of actives formulated for topical treatments is another
concern. While exposure to tacrolimus, when given as an ointment to treat atopic
dermatitis, is usually low [90], systemic absorption of the drug has been reported for 3
patients (3, 5, and 14 y old) with Netherton syndrome and erythroderma [91]. The systemic
absorption of topical steroids used to treat skin diseases has been frequently reported [92-
94], and some extreme cases have resulted in depressed adrenal function [93, 95] and
development of Cushing syndrome [93, 96]. It is well known that hydrocortisone
accumulates in the skin upon topical administration and, interestingly, application of a
moisturizer containing propylene glycol to the same skin site caused an increase in plasma
cortisol levels, presumably due to mobilisation of drug in the skin 'reservoir' [97].
3.3 Models for paediatric skin absorption
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Validated models, with which to predict skin absorption in paediatrics, particularly in the
premature and neonatal population, are scarce despite the persuasive evidence that both
effective transdermal drug delivery and systemic toxicity following unwanted skin
absorption are known to occur in these infants [2, 98-99]. An early compartmental
pharmacokinetic model [100] aimed to predict skin absorption in premature infants with no
effective SC (Fig 4). The zero-order release rate from a drug delivery system placed directly
in contact with the viable epidermis was described by k0 (mass.area-1.time-1). Drug diffusion
across the viable epidermis was characterized by k2 and the ratio k3/(k0/L.C)  (where C is the
drug concentration in the delivery system of thickness L) acts as a partition coefficient
accounting for the relative affinity of the drug between the viable epidermis and the device.
This model was used to interpret theophylline plasma levels measured as a function of time
in neonates [55]. A series of simulations were also performed to illustrate how changes in
the drug’s elimination rate constant, the release rate from the device, and its partitioning
behaviour affected the pharmacokinetic profile. Key obstacles to extend the approach to
other drugs include the estimation of sensible values for k3 and k2 in the absence of
experimental data and the integration of neonatal developmental and post-natal skin
barrier maturation into the model. Indeed, developing a device which adapts drug input to
the rapidly evolving skin barrier of the preterm infant represents a significant challenge. In
this sense, the vasoconstriction or blanching effect, observed post application of
Neosynephrine® to the internal surface of the thigh, has been suggested as a measure of
barrier maturity [101]. However, while infants with poor barrier function have been
successfully identified with this approach, the test remains qualitative. Further research
took the view that the epidermis of preterm infants resembles “the stripped skin of an
adult” and attempted to develop a model for pre-term skin based on tape-stripped pig ear
skin [102-103]. The key advantage of the approach was the quantification of barrier
impairment using TEWL (Fig.5). Significantly, the variation of TEWL as a function of the
percentage SC thickness retained in the laboratory model and as a function of post-
conceptional age (PCA) in neonates in vivo was strikingly similar. The correspondence
between these profiles therefore allowed barrier maturity to be predicted as a function of
PCA: for example, the SC of an infant at 200 d PCA would have only 40% of the mature
barrier; by 235 d, the competency would have increased to 75%. Another advantage of the
model was its use of readily available porcine skin to investigate and predict skin absorption
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in preterm neonates. It was suggested that drug permeability could be characterized for
model barriers with different competencies (0-100%) as defined by TEWL, and that
validation would require comparison of predicted and previously published data [56].
Subsequently, the permeation of lidocaine hydrochloride, phenobarbital and caffeine was
determined across differentially impaired skin barriers, and the steady-state fluxes were
fitted to the empirical equation: Jss = A.e(B.TEWL). The value of the constant A was sensitive to
the physicochemical properties of the drugs whereas B was similar for all three compounds,
suggesting that the level of barrier dysfunction causes comparable, relative effects on the
transport of different substances. Despite the significant promise of this approach, little
further work has been carried out to develop and validate the model.
A further question concerns variability and the challenge to achieve the appropriate drug
input rate in neonates with different levels of skin maturity and different dose
requirements. In this regard, the iontophoresis of lidocaine hydrochloride, phenobarbital
and ranitidine has been examined [103-105]. The rationale for the approach is that
iontophoretic transport is dictated by the relative mobility and concentration of ions
present both on both the epidermal and subdermal surfaces of the skin and is less
dependent on the inherent skin permeability (Fig. 5). In addition, iontophoretic drug input is
easily controllable by manipulating the intensity of current applied [106]. This was nicely
illustrated for lidocaine HCl: the cumulative amounts delivered passively across intact and
fully compromised skin were 0.7 ± 0.4 and 116 ± 69 µg.cm-2, respectively, whereas
iontophoretic delivery was much more efficient and essentially constant for the two
scenarios, 1837 ± 583 and 1979 ± 364 µg.cm-2 [103]. In the case of phenobarbital, [105] the
transdermal flux during iontophoresis increased with skin impairment and the complete
removal of the SC lead to a 3.6-fold enhancement relative to intact skin. Interestingly, it was
shown that iontophoretic flux remained constant and independent of the skin barrier
function, but that passive diffusion, which in this case contributed significantly to the total
transdermal flux, increased remarkably as the skin was progressively compromised and
eventually overshadowed any benefits from iontophoresis.
4. Paediatric use of transdermal therapeutic systems (TTS).
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Scopolamine (hyoscine): Transdermal scopolamine patches (Table 1) aim to prevent the
nausea, vertigo and vomiting associated with motion sickness and recovery from
anaesthesia. Scopolamine is potent, has a short-half-life and a high incidence of adverse
effects directly related to plasma concentration which, combined with its appropriate
physico chemical properties, makes the drug a good candidate for transdermal drug
delivery. The scopolamine TTS aimed to provide a longer duration of therapy and to avoid
peak and trough concentrations associated with side effects and lack of protection,
respectively [107]. On the other hand, relative to oral administration, scopolamine patches
must be applied 5-6 h before travelling due to slow drug absorption. Scopolamine patches
are considered effective to reduce post-operative nausea and vomiting (PONV) in adults but
a systematic review of this area excluded children [108]. While transdermal scopolamine has
been shown in reducing the incidence of PONV in children, the effectiveness is variable;
possibly because of the different timing of patch application relative to the time of surgery
[109]. Transdermal scopolamine has also been assessed for the management of sialorrhea in
children with developmental delays [110-111]. The labelling of scopolamine patches for the
treatment of motion sickness in children is inconsistent: Scopoderm TTS is approved for
children over 10 years whereas the label information of Transderm Scop and Transderm-V*
(essentially the same patch) precludes their use in children.
The APhA Paediatric and Neonatal Dosage Handbook (P&NDH) [60] suggests the use of
scopolamine patches for motion sickness in children older than 13 years; the BNFC [59] also
describes two unlicensed indications: the treatment of excessive respiratory secretions, and
of the hyper-salivation associated with clozapine therapy. A significant amount of
scopolamine in urine was found more than 2 days after patch removal in a study involving
hospitalized (3-18 y) children; this observation suggests the formation of a skin reservoir of
the drug (although whether this is important is unclear as adverse effects of the drug
subsidize quickly upon patch removal) [107]. Paediatric formulations should cater, ideally,
for a wide range of doses. In the case of transdermal patches, this is ideally accomplished by
using the availability of different sized patches or, in some cases, by cutting an original patch
to an appropriate size. The use of transdermal scopolamine patches to treat post-operative
emesis in 25 (1-11 y) paediatric patients following strabismus surgery has been described
[112]. One quarter of the original patch was used for patients under 2 years, and half a
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patch for older patients. In another study, 40 (6-14 y) children wore the uncut, complete
patch; and a significant reduction in PONV was observed for the first 48 hours (as well as a
greater incidence of dry mouth during the second and third days) [109]. One child suffered
hallucinations after the patch had been worn for 36 h that rescinded quickly after patch
removal. The BNFC [59] recommends use of a quarter of a patch (1 m-3 y) and half of a
patch (3-10 y) for younger children (see Table 1), aiming to reduce the excessive
anticholinergic side-effects as described above. However, caution should be taken when
cutting patches. For example, some of the visual disturbances observed upon transdermal
therapy have been attributed to the contamination of fingers (and subsequent transfer to
the eye by rubbing) with the drug through contact with the peeling layer [107]. Another
case involved a 14 y patient who removed his patch because of pruritus, and then rubbed
his eye [113]. Therefore, careful advice should be given to patients and carers to avoid these
unpleasant outcomes.
Fentanyl: Fentanyl patches (Table 1) are licenced to treat moderate to severe persistent
chronic pain in opioid tolerant children 2 y. Although not recommended, the BNFC
describes their possible use to treat severe chronic pain in “non-currently treated” 16-18 y
old children. Patient-controlled anaesthesia is not considered suitable for younger children
so transdermal patches provide a convenient alternative to nurse-controlled or continuous
IV administration; further, the youngest children may find it difficult to retain in place buccal
and sublingual formulations and swallow them resulting in considerable variability due to
subsequent and substantial first pass effect [114-116]. Based on adult data, and particularly
the incidence of respiratory depression in post-operative patients, it is sensible to avoid the
use of the fentanyl patches for post-operative pain in children. In the case of palliative care,
transdermal administration is convenient and minimally invasive for patients with
difficulties in swallowing and/or unacceptable morphine side-effects [116-117]. It should be
noted that, because percutaneous absorption is invariably slow, passive patches cannot
provide acute pain control. To address this limitation, the iontophoretic system, IONSYSTM,
was developed although it was not recommended for patients under 18y and the labelling
indicated that paediatric subjects might be more prone to skin local effects [118]. There are
several generic and therapeutically equivalent fentanyl patches of reservoir and matrix
types. The Duragesic patch, originally developed by Alza Corporation, had a reservoir of
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fentanyl base in alcohol gelled with hydroxyethyl cellulose and a rate-limiting membrane
which provided a drug input rate of 2.5 µg.h-1.cm-2; different patch areas (10-40 cm2)
allowed delivery from 25 to 100 µg.h-1. The current Duragesic is a matrix drug-in-adhesive
patch and is also available in a size that permits delivery at 12.5 µg.h-1. This system is of
interest since the delivery rate provides an equivalent dose to the 20-40 mg.day-1 of
morphine frequently used in paediatric cancer pain control [116, 119]. It should be pointed
out that a significant amount of fentanyl remains in the patch after use, and that the careful
disposal of used systems is essential given their potential for abuse and accidental exposure.
The pharmacokinetics of transdermal fentanyl in children and adults are quite similar [114,
120]. The terminal half-life after patch removal has been reported to be 14.5 h which
suggests that a skin reservoir of the drug has built up during the application period [114].
Because fentanyl pharmacokinetics are very variable, a wide range of concentrations are
observed after transdermal administration (Fig. 6); nonetheless, the patch avoids the
uncertainty and risks associated with the well-known (and, also very variable) hepatic first-
pass effect.  In 41 (2-18 y) children requiring opioid therapy, transdermal fentanyl was
effective and acceptable; the median dose at 15 days was 1.9 µg.h-1.cm-2 rising to 3.2 µg.h-
1.cm-2 to provide for the rapidly increasing pain experienced by patients with terminal
cancer [117, 121]. Younger (<10 y) children required higher weight-normalized doses than
older children, an observation in agreement with previous work which found that
transdermal clearance in children with cancer was inversely related to body weight [120]. In
addition, a higher weight-normalized volume of distribution has been found for neonates
and infants [119]. Subsequently, it was confirmed that the patch was useful and well-
tolerated in 199 (2-16 y) patients with severe pain and validated the recommendations to
convert from oral therapy; in this study, the initial daily dose was 0.98 ± 0.057 µg.h-1.kg-1,
increasing to 1.20 ± 0.09 µg.h-1.kg-1 over the first 15 days [122]. Use of the new, 12.5 µg.h-1
patch has resulted in smaller increases in dose requirements, perhaps because this system is
intended for earlier stages of treatment. A comprehensive review on the use of fentanyl
patches, including pharmacokinetic considerations is available [119].
Most of the side effects reported after transdermal fentanyl have been due to the drug
itself. However, adhesion problems (usually solved by additional application of medical
tape) and pain on removal due to excessive adhesion have been reported [116-117, 119-
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120]. Adhesion may be reduced by movement, skin condition (oily skin), sweating, and
behaviour (picking the patch). The skin should be clean and dry before application, and the
use of soaps, heat sources, lotions, oils and alcohol -based formulations at the skin site
should be avoided. The labelling provides extensive information to patients and carers with
comprehensive advice on the correct use and disposal of patches; this is crucial given the
high potency of the drug and its potential toxicity [118, 123].
Clonidine: Catapress-TTS® is a reservoir patch that provides continuous delivery of clonidine
for 7 days (Table 1). The label information (revised 0ct 2011) indicates that safety and
efficacy in paediatric patients have not been established in adequate and well-controlled
trials [118]. It is not listed in the BNFC, but the 19th Edition of the APhA P&NDH [60]
indicates that children can be switched to transdermal clonidine once an optimal and stable
oral dose has been titrated for the treatment of ADHD, hypertension and neuropathic pain
[60, 121]. The perceived advantages of the patch are the attainment of consistent levels of
drug and the potential for increased compliance [121, 124-125]. As with many other
patches, a significant amount of drug remains in the patch at the end of the application
period and this has caused toxicity due to inadequate disposal or to unintended transfer of
the active [126]. Interestingly, rebound hypertension has not been a problem when patches
have fallen off and it is believed that the clonidine skin depot becomes a self-tapering
source [124]. The plasma concentration achieved with a given patch depends on the
individual renal clearance; usually, steady state concentrations are achieved after 4 days
and changes in behaviour begin after 2-3 days [124]. However, it takes about two weeks to
see effects other than non-specific sedation and about a month to produce a significant
clinical response.
Children are usually started on oral clonidine and then switched to an approximately
equivalent transdermal dose [124]. The prophylactic use of transdermal clonidine in 10 (2-
8.7 y) children to prevent the withdrawal syndrome commonly observed after several days
of deep sedation has been investigated [127]. A transdermal clonidine patch (50-100 µg.day-
1) was applied 12 hours before discontinuation of sedative infusions and elective extubation
and remained on the skin for 7 days. None of the 8 sedative-tolerant, high-risk patients
experienced significant withdrawal symptoms, in comparison to 2 patients who did not
received clonidine. Despite of the small numbers of patients studied, clonidine appeared to
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be effective for this application. The patch used in this work was not identified but it seems
likely (given the delivery rates) that it was cut to provide doses appropriate for different
patients. It has been suggested [124], that patches can be cut to individualize doses,
although this is strongly discouraged by the APhA P&NDH [60] which recommends the
alternative and safer method of simply blocking the unrequired area of the patch with
adhesive bandage to limit drug absorption. An 11 y old with hypertension and chronic
intestinal pseudo-obstruction (and therefore unable to take oral medication) was treated
with the transdermal clonidine and IV enalaprilat to successfully control blood pressure
[128].
Transdermal clonidine administration is also associated with adverse skin reactions such as
contact dermatitis, erythema and pruritus. These side-effects have been observed as much
as in ~40% of the children wearing the patch and develop within 2-3 wk [121, 124-125, 129].
Local dermatitis appears to be worse when a protective cover to ensure adhesion is applied,
and the use of a topical steroid cream (e.g., hydrocortisone) has been proposed to alleviate
skin irritation [125]. Two toxicity cases in children wearing clonidine patches address the
importance of patient and healthcare education on the appropriate use of transdermal
patches [125]. In one, a 15 y old with ADHD received an overdose of clonidine when his
mother accidentally peeled off the rate control membrane of the patch, in the other, a 6 y
old with ADHD developed urticaria under the patch and the resulting scratching may have
damaged both the patch membrane and the skin leading to enhanced skin absorption.
Methylphenidate: The prevalence of ADHD is as high as 5-10% in children and 2.4-5% in
adolescents [130-132]. Monotherapy with amphetamines or with methylphenidate (MPH) is
the first-line pharmacological treatment of ADHD [130]. The Daytrana® patch (Table 1), the
first transdermal system developed specifically for the paediatric population, contains
methylphenidate (MPH) and was initially approved by the FDA to treat ADHD in (6-12y)
children in 2006 and in (13-17y) adolescents in 2010. The patch is not listed in the BNFC and
has not been submitted for approval to the EMA [133]. Daytrana®, developed by Noven
Pharmaceuticals, is a matrix type patch which uses DOT MatrixTM technology. The drug is
solubilized in acrylic adhesive and then mixed with a silicone pressure sensitive adhesive;
this forms evenly dispersed pockets of concentrated drug but retains the adhesive
properties of the silicone [131, 134]. The product sales and share of the ADHD market were
27
$64.2 million and 2.1% in 2007 and $78.7 million and 1.8% in 2008 [135]. The short half-life
of MPH means that multiple oral doses are required each day; while oral extended release
formulations are available, they do not always provide adequate treatment for a complete
school day. The patch meets a recommendation that treatment should be extended beyond
school hours and also caters for patients with swallowing difficulties [132, 134]. Thus, the
transdermal patch allows once-daily administration and avoids the drug’s substantial first-
pass effect (Foral is 25% and 1%, respectively, for the d- and l-enantiomers). Treatment is
usually started with a 10 mg (12.5 cm2) patch worn for 9 hours; the dose can be increased
by 5-10 mg.week-1 up to a maximum of 30 mg.day-1 (37.5 cm2 patch) [136].  MPH optimized
doses appear to be lower when patients are also enrolled in behavioural treatment [132].
Several studies have characterized the pharmacokinetics, efficacy and safety of the MPH
patch in paediatrics (Table 2) [131, 134-137]; an extensive review summarizes pre-clinical,
clinical and post-marketing studies as well as the data on efficacy and tolerability [132].
Briefly, the linearity of Cmax and AUC  for patches of different sizes has been shown; it takes
~7-9 h to reach Cmax although the onset of effects can be observed after 2 hours [131]. MPH
is a racemic compound and the d-enantiomer is more active; the total clearance is 0.4 and
0.73 L.h-1.kg-1, respectively, for the d- and l- enantiomers; consequently, the systemic levels
of l-MPH are ~60-73% of those of d-MPH [131]. The terminal half-life upon patch removal is
~3 h for d-MPH and 1.5h for l-MPH. Because both clearance and first-pass effect are stereo
selective, the d/l enantiomer ratio differs after oral and transdermal administration [132,
136]. Typically, very low levels (if any) of l-MPH are detectable after oral administration
[130, 132, 136]; in contrast, they are significantly higher (x50 fold) after transdermal delivery
even though this enantiomer contributes only ~5-10% of the drug’s  pharmacological
activity. Application of the patch to an inflamed skin site reduced the d-MPH lag time to less
than one hour, tmax to only 4 h, and caused a 3-fold increase in Cmax and AUC [131]. The Cmax
of d-MPH was ~50% lower in 13-17 y old children than in those aged 6-12 y; it is unclear
whether this is due in any way to skin absorption differences given that changes in
bodyweight significantly impacts the pharmacokinetics of MPH after oral medication [132].
The pharmacokinetics of MPH after single and multiple doses of the transdermal patch and
of an oral OROS formulation have been compared in children (6-12 y) and adolescents (13-
17 y) groups [137]. In agreement with previous results, plasma concentrations were higher
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for the younger cohort, and d-MPH accumulation at steady-state was low (although greater
by 1.4-1.6 fold for the transdermal group). As expected, l-MPH plasma concentrations were
approximately half of those of d-MPH after transdermal administration and negligible after
oral OROS.
Overall, MPH patches are well-tolerated by the majority (>75%) of patients [132]. Cutaneous
reactions to the MPH patch have been reviewed and their management discussed [138].
Briefly, most cutaneous reactions reported during clinical trials have been mild to moderate.
No or only mild discomfort was reported by 73% of patients while 23% experienced
moderate but tolerable discomfort and just 2-3% found the patch severely intolerable.
There is a low incidence of allergic contact dermatitis when the patch is worn as prescribed
(9 h), and allergic contact urticaria is also a rare event. On the other hand, mild to moderate
erythema is common. The 12 month tolerability of the patch was investigated in a Phase 3
study in 327 (6 to 12y) children [139]. Application site reactions accounted for 6.7% of study
discontinuations and generally consisted of mild erythema associated with mild discomfort
at the patch site; all other adverse effects were characteristic of the drug itself and where
not associated with the route of administration.  Of the 22 who discontinued, 15 were
subsequently treated with oral MPH without evidence of systemic sensitization. Dermal
adverse effects included rash (n=6) urticaria (n=6), contact dermatitis (n=2), allergic
dermatitis (n=2), generalized pruritus (n=2) and skin hyperpigmentation (n=2). The patch
adhesion scores after 9 hours of wear were mostly (>96%) “essentially no lifting of patch
from the skin” or “lifting of some patch edges”.  Nevertheless, following additional studies,
the FDA has added a warning to the Daytrana® label regarding contact sensitization as one
subject (0.3%) was confirmed to be sensitized to MPH [132]. On a positive note, there was
no increase in stimulant abuse following the introduction  of the patch to the market [132],
perhaps because MPH extraction from the transdermal system is more. A voluntary
withdrawal of a limited number of patches took place in 2006-7 as it was reported that
parents and caregivers had difficulty removing the release liner [132].
Another placebo-controlled, double blinded investigation evaluated the effect of shortening
the wear time of the patch in 128 children (6-12 y) after they had been stabilized on an
optimal dose for 5 weeks [140]. On designated days, the children wore an active patch for
either 4 or 6 hours and onset of drug activity was observed at 2 hours post- application with
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the PERMP (permanent product measure of performance) scores being significantly
different to placebo. The scores decreased, consistent with the short half-life of the drug,
upon removal of the patch. These results suggest that the transdermal patch can provide
additional dosing flexibility, in that its premature removal facilitates a shorter response or
more quickly mitigates any signs of side-effects.
Transdermal MPH is not approved for children younger than 6 y although Daytrana® has
been used in three preschool children (47-67 m) who had not responded well to other
treatments [141]. In the absence of dose guidance for this age group, a slow titration
process was followed: Initially the smallest patch (12.5 cm2) was applied for 1 hour daily; the
wear time was subsequently increased by 1 hour every 2-3 days, up to 9 hours by the 4th or
7th week. Depending on response and tolerance, the next size patch (18.75 cm2) was then
adopted and worn for 9 hours.  Overall, the three children tolerated a maximum daily dose
of 8-15 mg and their condition improved. Adverse effects included mild erythema as well as
those associated with the administration of stimulants to pre-school children.
Daytrana® should normally be worn on the hip for 9 hours. Application to the hip and to the
scapular area for 16 hours have been compared, and inequivalence between the two sites
was found; MPH absorption from the scapular area resulted in lower plasma concentrations
and a smaller AUC; bioavailability was ~31% greater at the hip where patch adhesion was
slightly better [138]. Once again, parents, carers and patient education about the
application site and timing, the length of wear, the use of cosmetics and soap, patch
removal and storing are crucial for safe and effective therapy [133, 136].
Buprenorphine: The label information for the Butrans® and Transtec® patches (Table 1)
indicates that their safety and efficacy in patients under 18 y have not been established
[118, 123]. The APha [60] lists the transdermal buprenorphine patches as one of several
formulations to treat moderate to severe pain and opioid dependence but does not provide
advice concerning the paediatric use of these patches. Their unlicensed used is listed in the
BNFC. While the use of buprenorphine in paediatrics has been reviewed, information
concerning transdermal delivery is limited to case reports on pain treatment (but not
neonatal opioid abstinence syndrome) [142]. The patch delivering the smallest rate (see
Table 1) has been considered more appropriate for paediatrics. When BuTrans® was used to
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treat pain in 4 children (3-10 y) with chronic pseudo obstruction syndrome  pain control was
achieved using 5-10 µg.h-1 patches in combination with either a fentanyl nasal spray or
sublingual buprenorphine for breakthrough pain [143]. Local skin reactions, mild pruritus to
erythema, in 3 of 4 patients were treated with a topical steroid spray and, in one case, the
application time was reduced to 4 days. It was recommended that re-use of a skin site be
avoided for up to 4 weeks. In 16 (2-17 y) paediatric patients with cancer related pain,
buprenorphine patches applied to the chest, back or upper arm, and changed every 3 days,
were useful and well-tolerated. The dose rate was titrated from 8.75; 17.5; 35; 52.5; 70 to a
maximum 140 µg.h-1. The smallest inputs were obtained by cutting the 35 µg.h-1 patch into
2 or 4 pieces to provide either ½ or ¼ of the delivery. After 2 weeks, ~70% of the patients
had responded to transdermal buprenorphine although some required rescue medication;
the mean dose was 32.6±14.8 µg.h-1 and the range 8.75-70 µg.h-1 [144].
Tulobuterol: The tulobuterol patch (Table 1), commercialized as Hokunalin® Tape in Japan
and Korea, and as AmiaidR in China, aims to improve the respiratory distress associated with
airway obstruction in bronchial asthma, acute bronchitis, chronic bronchitis and
emphysema. The label indicates its use for 6 m or older children. This potent bronchodilator
was extensively used in oral formulations, but the patch was developed to alleviate the so-
called “morning dip”, or decrease of respiratory function, experienced upon waking by many
asthma patients. The matrix type patch contains both crystallized and molecular forms of
the drug in an adhesive layer; the solid drug provides a reservoir to maintain the sustained
and continuous delivery of the drug [145]. The drug plasma concentration peaks 8-12 hours
after patch application in adults; hence, a patch applied at bed-time is able to control early
morning symptoms [146]. The patch is also suitable for children who have difficulties in
taking oral tablets. The pharmacokinetics of tulobuterol after transdermal administration
have been assessed in 6 boys (4-13 y) with previously controlled moderate to severe asthma
but admitted to hospital following a severe, acute, attack [146]. The patch, containing 0.2
mg.cm-2, was applied to the chest for 24 hours. The doses were 1 mg (30 kg) and 2 mg (30
kg) depending on body weight. Plasma levels started to increase 4 h after application and
Cmax was attained at 12 hours (Fig.7); drug concentrations decreased gradually after patch
removal. The peak expiratory flow rate significantly increased after application and was
significantly higher than control 22 h after patch application; this result further supports the
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hypothesis that a patch applied at bed time would prevent the “morning dip” efficiently. No
side effects were reported.
Oestrogen therapy: Treatment with oestrogens may be required for the development of
female secondary sexual characteristics. According to the BNCF [59], puberty can be induced
with increasing doses of ethinylestradiol and as guided by breast staging and uterine scans;
cyclical progestogen replacement is added after 12–18 months of oestrogen treatment.
Once the adult dosage of oestrogen has been reached, a low-dose, oral oestrogen-
containing contraceptive is advised. Nevertheless, most of these treatments are unlicensed
and the use of transdermal patches is not specifically described (Table 1). The AphA 19 th Ed.
[60] indicates the use of transdermal estradiol patches such as Climara®, Alora®,
Estraderm®, Menostar® and Vivelle Dot® to treat female hypogonadism. While the label
information of some of the patches includes their possible use to induce puberty, and
indicates the risks associated with large and repeated doses of estrogen over a long period,
there is no information specified about their efficacy and safety in children [118].
Traditionally, the induction of pubertal development in girls had been managed with oral
estrogens. While effective, this therapy has disadvantages, such as variable bioavailability
due to intestinal and hepatic first-pass effects as well as changes in liver activity and blood
clotting [147]. Further, the treatment has to be delayed with respect to the age of
spontaneous puberty to avoid a negative impact on the patient’s final height, often resulting
in some psychological sequelae [147]. Key advantages of the transdermal approach is
avoidance of pre-systemic first-pass effects and the availability of matrix patches, which can
be cut into smaller systems to pieces allow puberty induction to be started earlier using very
low doses [147-149]. A clinical study in 15 girls with hyper- or hypo gonadotropic
hypogonadism were treated with transdermal estradiol (Evorel® 25µg.day-1) [147]. Pubertal
induction was started for 12.3-18.1 y patients using a quarter of the patch (6.2 µg.day-1)
applied to the buttock at night-time; the dose was reduced to 4.2 µg.day-1 in some patients
with high (>40 pmol.L-1) serum estradiol. The initial dose was maintained for 4-14 months to
mimic hormone levels in early puberty and to prompt breast development to stage 2.
Subsequently, the dose was increased to attain mid-puberty levels and development to
breast stage 3. Progestogen was added to the estradiol treatment within 2 years of
induction. The results indicated that the procedure allowed the spontaneous levels and
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diurnal variation of serum 17--estradiol in early puberty to be achieved, but that further
refinement would be required to mimic levels in mid puberty. Breast development
(corresponding to breast stage 2) occurred in 12 of the 15 girls within 3-6 months of the first
patch application.
Ovarian failure affects ~90% of females with Turner syndrome (TS) and requires hormone
replacement therapy [149]. A one year study in 12 (14.0 ±1.7 y) girls with TS compared oral
versus transdermal estrogen (Vivelle TD system) treatment for pubertal induction [149]. The
transdermal group was treated with a 25 µg patch twice a week for 6 months, followed by a
37.5 µg patch twice a week for the second 6 months. The oral oestrogen dose was 0.3
mg.day-1 every day for the first 6 months, followed by alternating 0.3 mg and 0.625 mg daily
doses for the next 6 months. The transdermal treatment resulted in a greater change in
spine bone density (bone mineral density and content) and greater increases in uterine
length and volume. No differences were found in other parameters such as IGF-1 and lipid
profile, or growth velocity and body composition. At the end all bar two girls, one in each
arm of the study, had progressed to Tanner stage III-IV.
A 2011 investigation on 128 (13.5±0.5 y) girls with Turner syndrome revealed a significant
increase in the use of transdermal oestrogen over the preceding 4 years reflecting,
presumably, the view that the patches provide a more physiologic and favourable mode of
oestrogen replacement [150]. The literature through 2013 comparing oral versus
transdermal exogenous pubertal induction has been reviewed, and dose equivalences
between the two therapeutic approaches has been pondered [148]. Although transdermal
therapy seems promising, there is clearly a need for large-scale, multicenter studies to
properly validate the positive results from the limited (in terms of patient numbers)
assessments performed to date.
Nicotine: The numerous nicotine transdermal systems available in the market (Table 1) aim
to treat nicotine withdrawal symptoms (NRT). According to the FDA labels [118] medical
advice should be sought for individual younger than 18 y. In the EU, several nicotine patches
are authorized for the 12-18 y old population although, due to the lack of information
concerning this age group, medical advice is recommended after 3 weeks of treatment
[123]. In 2009, in England, 52% of 15 y olds had tried smoking and 15% were regular
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smokers. Providing help to adolescents to quit successfully is a public health target because
most regular smokers start during adolescence. As a result, NRT formulations were made
available to all 12-17 y old in 2005 in the UK [151]. An analysis of the changes in NRT
prescribing between 2005 and 2009 revealed that it was highest for 16-17 y olds and lowest
for the 12-13 y age group (less than 10 prescriptions per 100,000 adolescents per month)
[151]. It was concluded that the recent licensing modifications in the UK had little effect on
prescribing practice. A later, self-reporting study from the USA found that 5% (n= 4078) of
11th graders (16-17 y) reported current or former NRT use; the exclusive use of gum (42%)
was twice as likely as the exclusive use of a patch (29%) [152].
Attempts to quit, typically motivated by concern about current and future health, are
common among young smokers [153]. However, the efficacy of NRT in adolescents is
considered to be lower than in adults (although it has been successful in some trials
involving highly addicted (>10 cigarettes.d-1) participants with substantial comorbidity
[153]). A 2011 meta-analysis found that NRT for smoking cessation in adolescents had no
significant effect on abstinence rates at short and mid-term follow-up (<26 weeks) [154]. It
was also pointed out that most trials have involved a limited number of participants and
that low compliance may be contributing factor. Few adverse effects, mostly itching (33-
62%) and redness (15-52%), have been reported when using nicotine patches [154]. A
double-blind, placebo controlled trial of a nicotine patch involved 100 (13-19 y) subjects,
who had smoked at least 10 cigarettes per day in the last 6 months, did not use any other
tobacco product more than once a week, were motivated to quit smoking, and were not on
any other NRT product [155]. The most common adverse effects (but not considered
serious) were itching and redness at the skin site, sleep problems and abnormal dreams,
joint, muscle and stomach aches, and light-headedness. Participants using the nicotine
patch reported fewer withdrawal symptoms, including craving, and while it was concluded
that the patch might be a promising medication, further trials were considered necessary.
The use of transdermal nicotine to complement the effects of haloperidol in the treatment
of Tourette’s syndrome has also been proposed [156]; the first trials involved nicotine gum
but, despite beneficial effects, patient compliance was limited by the bitter taste and by
gastrointestinal effects. Results from the mostly uncontrolled studies have been
summarized [156].
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Other actives: The use of transdermal selegiline (EMSAM) in paediatrics has been
investigated [157]. However, because of concerns about the use of antidepressants in
children and adolescents, and an increased risk of suicide, the patch is not approved for
paediatric use [118]. Concerning the contraceptive patch, ORTHO EVRA®
(norelgestromin/ethinyl estradiol), the label indicates that safety and efficacy have been
established in women of reproductive age, i.e., both for post-pubertal adolescents under 16
y and for those 16 and older [118, 158]. For EVRA patch, (which delivers oestrogen at a
greater rate) the label information indicates that its use and efficacy has been established
only for women > 18y [123].
5. Innovative methods for paediatric transdermal drug delivery.
The latest advances and state-of-the-art in methods to enhance transdermal delivery, and
therefore expand the number of drugs deliverable by this route of administration, have
been recently reviewed [6]. Enhancement methods are broadly classified into non-invasive
approaches that maintain the integrity of the SC and minimally invasive strategies that
disrupt the SC barrier.
Iontophoresis uses a small electrical current (<0.5 mA.cm-2) to enhance molecular transport
across the skin and can be used for drug delivery and non-invasive sampling applications
[106]. This technique is probably the most established among the non-invasive methods,
which apply a source of energy to enhance skin permeation. Indeed several iontophoretic
devices have been approved and marketed [106]. The earliest paediatric application was the
iontophoretic delivery of lidocaine to provide local anaesthesia prior to venous sampling
and minor dermatological interventions. Implementation first involved the use of a power
supply (Iomed® Phoresor II Auto) and disposable electrodes, which could be either filled
prior to use by the practitioner [159] or prefilled (NumbyStuff®) [160] with a solution
containing 2% lidocaine and 1:100,000 epinephrine. The second active aimed to induce local
vasoconstriction and reduce lidocaine clearance into the systemic circulation. Compared to
the conventional EMLA cream (2.5% lidocaine and 2.5% prilocaine) iontophoresis provided a
faster onset of anaesthesia and, sometimes, in children, a greater depth of dermal
penetration [160-161]. The efficacy of iontophoresis versus placebo in children has been
demonstrated [159, 162]. In 13 patients, 11-19 y, iontophoresis was compared with
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subcutaneous injection, which was more painful but more effective; similar levels of anxiety
were generated by both methods [163]. While the preponderance of evidence suggests that
iontophoresis is a safe and effective method, there is disagreement about the level of
paediatric satisfaction; this is probably related to the different iontophoretic procedures
followed and to the age of the patients involved. Some practitioners have found
iontophoresis a complicated method as compared to EMLA cream application.
A significant improvement, therefore, was the development of the LidoSite® device by
Vyteris, Inc. (Fair Lawn, NJ) that was approved by the FDA in 2005 (although it is no longer
commercialized). The system comprised (a) the single-use, disposable LidoSite® Patch which
contained a 5 cm2 drug reservoir, and (b) the LidoSite Controller, a portable,
microprocessor-controlled, battery-powered DC current source sufficient for up to 99 drug
(1.77 mA-10 min) applications. This iontophoretic lidocaine delivery system was small, easy
to use and pre-programmed, therefore minimizing variability in the dose and rate of
anaesthetic administration. A study in 12 healthy children found that the system was well
tolerated. An optimized formulation (10% lidocaine and 0.1% epinephrine) was used and
provided anaesthesia in only 10 minutes; systemic exposure to lidocaine was very low with
11 out of 12 subjects showing concentrations below the LoD (5 ng.mL-1), and the other
slightly more (8.9 ng.mL mL-1) [164]. Quite likely, the increased content of lidocaine
(compared to previous formulations) resulted in a larger drug transport number (and
iontophoretic flux) [165]. The reduced epinephrine content was selected to achieve a
degree of vasoconstriction so that the local anaesthetic residence time was adjusted
appropriately without compromising the venipuncture procedure. The effectiveness of the
iontophoretic delivery of a lidocaine/epinephrine for the provision of tympanic membrane
anaesthesia to treat acute, chronic and recurrent otitis media was the object of a non-
randomized, multicentre, prospective, clinical study sponsored by Acclarent which involved
12 months and older children according to the data base ClinicalTrials.gov. [166];
unfortunately, no results have yet been posted.
The iontophoresis of dexamethasone phosphate, a common procedure in physiotherapy,
was recently tested for the treatment of temporomandibular joint involvement in juvenile
idiopathic arthritis (JIA) as a less invasive alternative to intra-articular steroid injections
[167]. The study involved 28 (2-21 y) JIA patients, most of whom completed the 8-10
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iontophoresis sessions. Approximately 2/3 of the subjects experienced an improvement or a
normalization of the temporomandibular joint range of motion and the associated pain
[167]. While this small study suggests that dexamethasone iontophoresis is safe and
effective, further studies are required to determine the optimum dosing and to compare
iontophoresis with intra-articular steroid injections. Iontophoresis has been suggested as an
approach to deliver other actives such as methylphenidate [168], ranitidine [104] and
phenobarbital [105]. While these investigations have sometimes suggested the feasibility of
delivering therapeutic doses, at least for some age groups, only in vitro studies have so far
been carried out (Fig.5).
Iontophoresis can also be used to non-invasively sample drugs and clinical markers. The
Glucowatch Biographer® (developed by Cygnus, Inc.), which was able to monitor blood
sugar over the entire range of glycaemia, received a CE Mark for children (7-17 y) in 2000
and FDA paediatric (7-17 y) approval in 2002. This device provided the first truly non-
invasive approach to the monitoring of blood glucose and was considered accurate and safe
[169]. However, use of the device provoked some irritation (itching, swelling, mild to strong
erythema) which obliged application sites determined to be rotated, a perceived limitation
in smaller patients. An interesting feature was the “down alarm” which signalled a 25% fall
in the blood glucose concentration and a possible, impending hypoglycaemia, which might
then be prevented. However, it was later reported that the decreased accuracy of the
Glucowatch Biographer® at lower glucose levels meant that the alarm setting required to
detect a high proportion of hypoglycaemic events would result in a high number of false
alarms [170]. Regrettably, the commercialization of the device was suspended in July 2007
and the Glucowatch Biographer® is no longer available. Subsequently, and primarily in
adults, iontophoresis has been used to sample phenyl-alanine (phenylketonuria) and
markers of renal disease such as urea and iohexol [106].  A small pilot study in paediatric
patients suggested the possibility of assessing glomerular filtration rate via the
iontophoretic extraction of iohexol [171].
Other innovative, passive patch technologies have appeared. The S-Caine PatchTM (ZARS
Inc.) (Table 1) includes a drug reservoir containing a 1:1 eutectic mixture of lidocaine and
tetracaine and excipients (polyvinyl alcohol, sorbitan monopalmitate, water, methylparaben
and propylparaben) (Fig. 8). The CHADD, controlled heat-aided drug delivery system,
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comprises iron power, activated carbon, sodium chloride, wood flour, water and filter paper
[172]. Upon removal from the protective pouch and exposure to atmospheric oxygen, an
exothermic reaction occurs causing the patch heat up and increasing skin temperature by
~5C [173]. The effectiveness of the heat-aided patches was first demonstrated in adults
[174], and the device was commercialized as SyneraTM (USA) or RapydanTM (Europe) and
approved for paediatric use [175]. The surface area of the patch is 50 cm2 but drug is
delivered through only 10 cm2. According to label information, safety and efficacy have
been established in paediatric patients 3 years and older in well-controlled studies, whereas
only safety has been demonstrated in a clinical study involving 34 children of 4-6 months
[118]. In an investigation with 64 (3-17 y old) children, either the S-Caine PatchTM, or a
placebo (including the CHADD component) was applied for 20 minutes prior to venous
access. The S-Caine PatchTM considerably reduced pain compared to placebo; a 100%
success of vein entry and cannulation was reported for both groups, partially explained, at
least, by a heat-induced vasodilatation effect. In 40 (3-17 y) patients, who required IV
catheter access, the SyneraTM patch (mean application 39 min) was evaluated against an
identical placebo (mean application 33 min) that also contained the CHADD element [176].
Ease of cannulation was similar for both groups but more subjects using the SyneraTM patch
reported adequate anaesthesia. EMLA and RapydanTM patches were compared in 200 (3-13
y) children [177]. The application time was 35 minutes in both cases; visibility of veins and
success of a venipuncture procedure were the same for both groups, while erythema was
more frequent for the RapydanTM treated children, who also experienced less pain. The
latter outcome was not unexpected, however, as the EMLA patch should be applied for at
least 1 hour before the intervention. The systemic exposure to lidocaine and tetracaine
depends on the number of SyneraTM (or RapydanTM) patches worn and the duration of the
application. For example, the simultaneous application of two patches for 60 minutes
resulted in plasma lidocaine concentrations of 16.8 ng.mL-1 and 2.1 ng.mL-1 in children aged
3-6 y and 7-12 y, respectively; tetracaine was < 0.9 ng.mL-1 for all age groups [173]. The
EMLA system (Table 1) is available in Australia, France and Canada, and is essentially a patch
version of EMLA cream that aims to provide easier use and more precise therapy [60, 178].
While the EMLA patch can be applied to younger children (under 3 months but not
newborns) it must be applied for at least an hour to achieve adequate local anaesthesia.
Nevertheless, the efficacy of the EMLA patch in the paediatric population has been reported
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[178-184]. The LidoDerm® product (700 mg of lidocaine in an adhesive patch of 140 cm2)
(Table 1)  is indicated for the treatment of post-herpetic neuralgia in adults and its safety
and efficacy has not been established in children; nevertheless this patch was compared
with a placebo in 72 paediatric (4-15 y old) patients. It was found to be effective in reducing
the pain of venipuncture but not that associated with rocuronium injection [185].
Among the so-called minimally invasive technologies, liquid-jet and powder-jet injectors
have been proposed for the delivery of vaccines, insulin, sumatriptan, and human growth
hormone. Some of these devices have been commercialized and tested in children [6, 186-
188]. In particularly, significant work has been undertaken with respect to the delivery of
growth hormone, with several devices (Medi-Jector®, ZomaJet® 2 Vision, SeroJet®,
Genotropin® ZipTip, Cool.clickTM) already tested and commercialized as recently reviewed
[188]. However, discomfort and local side-effects may limit their application in children [6,
188]. The Biojector® 2000 is a needle-free system cleared by the FDA to deliver
intramuscular injections; it can also deliver subcutaneously and has also been tested for
intradermal administration in clinical trials [118]. For example, the ability of the Biojector
2000 to inject intradermally a fractional dose of an inactivated poliovirus vaccine was
compared to the intramuscular injection of the full dose in 471 infants at weeks 6, 10 and 14
of age [189]. A greater number of minor local reactions (induration, redness and pain) was
observed with the needle-free injector which was the method preferred by parents.
However, a lower immunogenicity was observed for the intradermal injection, possibly due
to the different doses administered. In another study, 50 children (4-10 y) with diabetes
were asked to compare one administration of saline with the needle free device “cool.click”
to their morning insulin needle injection [190]. Adverse reactions to the “cool.click” device
included minimal bleeding, without hematoma, bruising and skin lacerations. Pain or
discomfort was absent in 52%, slight in 40% and severe in 8%; 38% of children had no fear,
no worry; 52% had little fear/worry; and 10% were very worried. Overall, the children found
the needle-free device easier to use and more comfortable than their insulin needle
injection, and 74% preferred it over needles. Another investigational, single-use, disposable
powder-jet injector (ALGRX 3268), which delivered powdered lidocaine (0.35 µm particle
size) was investigated in 145 (3-18 y) children for its ability to reduce pain before
venipuncture [191]. A placebo (empty drug cassette) and injectors delivering 0.25 and 0.5
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mg of lidocaine were compared; all three contained helium gas pressurized at 20 bar. The
system was effective compared to placebo, and required only 2-3 minutes to provoke
anaesthesia, much shorter than the 10-15 minutes and 30-90 min required for iontophoretic
and passive formulations, respectively. Patients using the active injector were more likely to
develop erythema and petechia.  A randomized, double-blind, sham, placebo-controlled,
single-dose phase 3 study evaluated the efficacy and safety of an intradermal powder
injection device  involving 579 (3-18 y) volunteers undergoing venipuncture or cannulation
procedures [192]. The device contained 0.5 mg lidocaine hydrochloride monohydrate (40
µm) and medical grade helium (21 ± 1 bar); the sham placebo device was identical except
that lidocaine was absent.  The active system was described as more effective than the
sham placebo. Dermal reactions (erythema, petechia) were “minor, short-lived and self-
limited”. Again, the greatest benefit of this device was that the analgesic effect occurred
within 1-3 minutes after administration. The J-Tip® is an FDA-approved injection for inducing
local anaesthesia; in this case, buffered lidocaine is delivered under high pressure from a
compressed carbon dioxide gas cartridge, allegedly to a 5-8 mm depth in 0.2 seconds [193].
The system has been compared to EMLA cream in 116 (7-19 y) volunteers and was well
tolerated; further, according to the authors, the J-Tip® provided faster anaesthesia than the
cream and was cost-effective.
Microneedles (MN), another example of new, rapidly evolving technology, are described as
an array of micro-projections, typically from 25 to 2000 µm in height, of a variety of
different shapes, and attached to a base support [194-195]. Upon application to the skin
surface, the MN open transport pathways of micron dimensions across the SC.
Comprehensive reviews on MN including their fabrication, classification, available devices
and their applications in drug delivery, including immunization, are available elsewhere
[194-196]. MN effectively bypass the SC barrier and therefore expand the applications of
transdermal drug delivery to large molecular size entities. Nevertheless, because MN are
most suitable for the administration of relatively small doses, they have been primarily
targeted to large and potent drugs such as biopharmaceuticals. Although the use of MN to
deliver disease modifying antirheumatic drugs in paediatrics is considered to be potentially
advantageous, they have been tested in children on only limited occasions [186]. The
delivery of desmopressin using a MN array (Macroflux®) to hairless guinea pigs was efficient
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and well tolerated, suggesting its potential use to treat enuresis in young children [197].
Two studies [198-199] investigated the delivery of insulin to children and adolescents with
type 1 diabetes. The first in 5 subjects compared the delivery of intradermal insulin via a
single hollow microneedle with subcutaneous insulin administered via a catheter
administration [198]. There were no differences in insulin AUC but absorption was faster for
intradermal insulin as indicated by tmax (27 ± 13 min and 57 ± 20 min for MN and catheter
administration, respectively). The pain associated with inserting the MN was significantly
less than that associated with the catheter, but there were no differences in the pain scores
related to insulin infusion. There was less erythema associated with MN, but the new
administration method resulted in more oedema, described as a “fluid bleb”, which was due
to displacement of the skin surface by the insulin solution. The second study, in 16 (10-18 y)
participants, compared intradermal (MN) and subcutaneous (syringe pump) routes of
administration [199]. The hollow microneedle was inserted into the abdomen and this
procedure was reported as less painful. The pain scores associated with the insulin infusion
were higher for the MN (although the difference was not significant). It was suggested that
lowering the flow rate, addition of hyaluronidase, and increasing the MN size to reduce the
infusion pressure would improve the acceptability of the approach.  Another investigation in
384 (4-66 m) children has evaluated skin thickness (epidermis + dermis) at four different
body sites (deltoid, suprascapular, upper back and lumbar area) considered suitable for
intradermal vaccine injection [200]. Skin thickness did not depend upon age, gender, BMI,
and phototype, but was significantly higher (a) at the suprascapular area (1.30 mm) than the
deltoid (1.22 mm), and (b) on the upper back (1.39 mm) than the lumbar area (1.31 mm).
However, these differences were considered clinically irrelevant with respect to vaccine
delivery meaning that MN of different lengths would not be needed to routinely vaccinate
children aged up to 5 years.
Other minimally invasive techniques, such as thermal microporation, are at different stages
of development. The effect of laser-ablation of the SC prior to application of a lidocaine
cream was investigated using a FDA approved, lightweight and portable Er:YAG unit with a
fluence of 3.5 J.cm-2 and a spot diameter of 6 mm; the control was a sham laser [201]. The
laser exposure time was 600 µs and the cream was applied for 5 minutes. Adults and 15 (3-
17 y) children were studied and the procedure was reported to be effective and did not
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provoke any persistent erythema or infection. However, any conclusions were limited by the
small number of children involved in each age group. Elsewhere, the SonoPrep®
(sonophoresis) device was used in 50 (5-10 y) children again to reduce the time required to
achieve local anaesthesia following application of EMLA cream [202]. The skin site was
treated with either the SonoPrep® or with sham sonophoresis, and the cream then applied
for 5 minutes. The SonoPrep® intervention reportedly caused minimal discomfort (with only
2 of 21 children complaining of minor skin reactions) and reduced the pain due to IV
cannulation. However, while the pain scores were determined by blinded researchers, the
children’s parents were not; further, subject numbers were probably too small to detect any
rare side-effects of sonophoresis and, finally, the control group received no effective pain
relief because a 5-minute EMLA application is insufficient for this purpose. It follows that a
more objective study design is required to substantiate the conclusions of this work.
6. Conclusions
TDD has been successfully translated from adults to the paediatric population primarily in
the form of patches which, in some cases, were specifically developed for the paediatric
population. An important disadvantage of passive patches is the significant amount of drug
remaining in the patch upon its removal after use.  For example, only 36% of the MPH
loading in a Daytrana patch is absorbed during a 9 h application [133]. Obviously, the drug
left in the patch provides the opportunity for abuse and accidental exposure [141]. A
different risk occurs when a transdermal patch is worn by an adult and inadvertent transfer
to children occurs. Other problems occur when, for example, the same patch is applied
twice, a patch is applied for too long, or increased skin absorption is caused by use of
heating pads [203]. Comprehensive advice must be provided on the correct use and disposal
of transdermal patches independent of the age of the patient. The potential for irritant
contact dermatitis and allergic contact dermatitis should be considered (but, for most drugs,
only mild effects are seen; moderate erythema is the most common skin-effect) [138].
Again, education is crucial to reduce the incidence of contact dermatitis and to respect the
site and duration of application [138]. Poor adhesion has also been reported as a limitation
with respect to the use of transdermal patches [138,204-205].
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Not all the marketed patches are licenced for paediatric use. Some patches are used
unlicensed and lack an appropriate range of doses (areas) for paediatric therapy. As a result,
health carers frequently cut patches proportionally to the dose reduction required. The
practice of cutting patches is routinely discouraged by manufacturers and, in fact, there is
little information about the risks (either of over- or under- dosing) involved. There is a
general pre-assumption that the risk of toxicity associated with drug leaking from a patch is
greater for reservoir patches systems but this may not always be the case (as shown
recently for a fentanyl product) [206]. As a corollary, extrapolating a practice established as
safe for a given patch (brand or formulation) to another patch containing the same drug
without consideration of differences in structure and composition may result in unexpected
outcomes.
On the positive side, transdermal patches have improved drug therapy in children. This is a
non-invasive route of administration which avoids first-pass effects (oestrogen and ADHD
therapy) and provides controlled and prolonged plasma levels. For example, the bed-time
application of the tulobuterol patch ensures appropriate plasma levels upon waking the
following morning, and the MPH patch sustains drug delivery throughout the school day.
Patches are easier to use, especially for patients who experience difficulties in swallowing,
and are less disruptive to the daily routine of parents and carers, thereby facilitating
adherence. Finally, transdermal patches allow individual dose titration by modification of
either the patch size or wear time [135, 140-141].
Significant advances in innovative methods for transdermal drug delivery have been
achieved and these methods may be progressively translated to paediatrics as safety and
efficacy is established in adults. A specific example is iontophoresis, for which two devices
have been approved for paediatric use.
Nevertheless, major challenges remain with respect to the translation of TDD devices and
formulations to the premature neonates because of their immature and rapidly evolving
skin barrier function. Research is urgently needed in this area to ensure that this vulnerable
population enjoy the benefits of this unique, non-invasive route of drug delivery.
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Table 1
Drug BrandsArea/drug content/nominal rate Labelled and unlicensed uses
Scopolamine
(hyoscine)
Scopoderm TTS®
Transderm Scop
Transderm-V*
2.5 m2/ 1.5mg/ 1mg over 72 h
Label: Scopoderm TTS for  prevention of motion
sickness in 10-18 years
Unlicensed use:
BNFC:  Excessive respiratory secretions: 1m-3y:
quarter of a patch /72h - 3-10 y: half a patch/72h
and 10-18 y:1 patch/72 h
BNFC: Hypersalivation associated with clozapine
therapy: 10-18y:1 patch/72h
APhA: Motion sickness: >12y:1 patch/72h
Fentanyl
Duragesic DTrans®; Duragesic®
Fencino®, Fentalis®, Matrifen®,
Mezolar®, Osmanil®, Tilofyl®,
Victanyl® and several generics
Aproximate ranges:
5 to 42 cm2
2.1 to 16.8 mg
12.5 to 100 µg/h
Label: for management of persistent, moderate-to-
severe chronic pain in opioid tolerant patients
currently receiving opiates in > 2y.
Unlicensed use:
BNFC: severe chronic pain in 16-18y not currently
treated with strong opioid analgesic; although
warning about serious risks of fatal respiratory
depression.
Additional information: See labelling, BNFC and APhA
for several warnings concerning the use of
fentanyl and patches.
Clonidine
CatapresTTS®-1; -2; -3
3.5; 7.0 and 10.5cm2
2.5; 5.0; 7.5mg
0.1; 0.2 and 0.3 mg/day over a week
Label: safety and effectiveness not established in
paediatrics.-
Unlicensed use:
APhA: Management of hypertension, ADHD and
neuropathic pain. Children and adolescents can
be switched to transdermal after titration with
oral dose. The transdermal dose approximately
equivalent to the total oral daily dose may be
used.
Additional information: The patch contains aluminium
and must be removed before undergoing MRI
Methylphenidate
DaytranaTM
12.5; 18.75; 28.0; and 37.5 cm2
27.5; 41.3; 55; 82.5 mg
1.1; 1.6; 2.2; 3.3 mg/h during 9 h
Label: FDA approved for treatment of ADHD in 6-17 y
Additional information: (APhA): Long term use of the
patch (and other dosage forms) has not been
adequately studied and should be re-evaluated
periodically for the individual patient.
Buprenoprhine
BuTrans®
20.25; 30.6; 51.84 cm2
5, 10, 20mg
5, 10, 20 µg/h for 7 days
TransTec 35®; 52.5®; 70®
Active area: 25; 37.5; 50 cm2
20, 30 40 mg
35, 52.5, 70 µg/h for 4 days
Label: safety and effectiveness not established for <
18y; not recommended for paediatric use.
Unlicenced: moderate to severe pain
BNFC: Approximate equivalence provided for
BuTrans® and TransTec® patches and oral daily
doses of morphine.
APHa: BuTrans® listed without further advice
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Tulobuterol
Hokunalin Tape 2 mg (AmiaidR)
6m-2y 0.5 mg of the tape
3y-8y 1 mg of the tape
 9y 2mg of the tape
Label: improve respiratory distress caused by airway
obstruction of bronchial asthma, acute
bronchitis, chronic bronchitis, or emphysema in
 3 y.
Estradiol
Climara® ; Alora® ; Estraderm ®
Vivelle Dot®, Menostar®, and others.
2.5 to 25 cm2
0.39 to 8 mg
75 to 100 µg/h
Once weekly and twice patches
Label: safety and effectiveness in paediatric patients
not established although some labels indicate
their possible use for induction of puberty in
adolescents.
Unlabelled:
APhA: Female hypogonadism in adolescents. Use
lowest effective dose for shortest duration
possible consistent with an individual patient.
See APha dosing guidelines for once- and twice
weekly patches.
Additional information: Some of these patches contain
aluminium and must be removed before
undergoing MRI
Nicotine
NicAssist; Nicotinell TTS; NiQuitin;
Habitrol ; Nicoderm ; ProStep and
others.
Several presentations; range:
5-25 mg/16h or 7-21 mg/24h
Examples:
Nicotinell TTS 30: 30 cm2 active area/
52.5mg / 22 mg/24h
NiQuitin 14: 15 cm2 active area / 78
mg / 14  mg/24h
Label: Nicotine replacement therapy > 12y. Some
labels indicate seek medical advice after 3 weeks
treatment.
FDA: Seek medical advice for < 18y, some
patches not for sale for <18y
Additional information: See BNFC and specific product
labelling for dosing titration and guidelines.
Lidocaine:tetracaine
Rapydan®/Synera®
50 cm2 (active 10 cm2)
70 mg of each active
Label: Provide local anaesthesia for superficial venous
access and superficial dermatological procedures
for children  3y. Safety demonstrated in 4-6
months
Additional information: The patch contains iron and
must be removed before undergoing MRI
Lidocaine:prilocaine
EMLA® patch
40 cm2 (active 10 cm2)
2.5% of each active in each 1g patch.
Label: Provide local anaesthesia for minor procedures
(IV cannulation or venepuncture, superficial
minor surgery in neonates and older. Safety not
established in premature infants.
Lidocaine Lidoderm® and generics140 cm2; 700 mg
Not licensed for paediatric use.
Table 1: Details of transdermal patches that have been used in children and their labelled and
unlicensed uses. Information gathered from BNFC, APhA 19th Ed, and the Drugs@FDA, and Electronic
Medicines Compedium databases [59-60,118, 123].
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Table 2
Dose  (mg)
delivered in 9h
Patch size
(cm-2)
Nominal
delivery rate
(mg.h-1)
MPH content
(mg)
Cmax
(ng.mL-1)
AUC0-12h
(ng.h.mL-1)
d-MPH l-MPH d-MPH l-MPH
10 12.5 1.1 27.5 20.0 14.6 145 86.2
15 18.75 1.6 41.3 23.9 15.0 181 100
20 25 2.2 55 30.5 18.4 229 129
30 30 3.3 82.5 46.5 29.5 378 229
Table 2: Characteristics of the methylphenidate transdermal systems (Daytrana®) commercially
available to treat ADHD, and mean values of observed pharmacokinetic parameters: Cmax and AUC0-
12h.  The lower values of these parameters for the l-enantiomer of MPH are consistent with its higher
systemic clearance (see text for details). Data taken from references [118,131].
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Figure Captions
Figure 1: Skin blanching (left panel) following a 30 second application of 20 µL of a 1% epinephrine
solution and corresponding TEWL measurements (right panel) as a function of postnatal age for
infants born at < 30 weeks; 30-32 weeks; 33-36 weeks and  37weeks of gestational age. The drug
solution was applied to the same abdominal site immediately after TEWL was measured. The shaded
area indicates the range of TEWL in mature infants. See ref. for complete details. Reprinted from
Harpin et al., 1983 [29] with kind permission from Elsevier.
Figure 2: Top panel: In vitro phenobarbital flux across skin sourced from 7 preterm and full-term
deceased infants as a function of GA at birth; the PNA for each neonate is indicated. The drug
delivery system was 39 µL.cm-2 of a 2 mg.mL-1 phenobarbital solution in ethanol. Post-application,
the solvent was allowed to evaporate and the experiment was run for 12h. The dotted lines indicate
the corresponding flux (mean ± SD) for adult skin. Bottom panel: Diamorphine permeability
coefficient (Kp) across neonatal cadaver skin as a function of the GA at birth; PNA age was 1-3 days
unless specified otherwise. The donor formulation was 3.4 mL of a 2.5 or 10 mg.mL-1 diamorphine
solution in 0.1M acetate buffer at pH4; the experiments run for a maximum of 72 h. Data redrawn
from Bonina et al., 1993 [67] and Barrett et al., 1993 [68].
Figure 3: Lag time and flux of phenobarbital (mean ± SD; n = 3-5) measured across preterm, full term
infant and adult human skin, and through 6-9 wk hairless mouse skin. The formulation was 39 µL.cm-
2 of a 2 mg.mL-1 solution of phenobarbital in ethanol. Post-application, the solvent was allowed to
evaporate and the experiments run for 12h.  Data redrawn from Bonina et al., 1993 [67].
Figure 4: Schematic representation of the drug release and associated pharmacokinetic model
proposed describe transdermal drug delivery in preterm infants, who lack an effective SC.  The
various parameters are defined as follows: V1 and L are the volume and thickness of the drug
delivery device; V2 and Lve are the volume and thickness of the viable epidermis; V3 is the drug’s
volume of distribution; k0 is the zero-order release rate of drug from the device; k2 describes the
diffusion of the drug across the viable epidermis; k4 is the drug’s elimination rate constant. The ratio
k3/(k0/L.c), where c is the drug concentration in the device, is an “effective partition coefficient”.
Redrawn from Evans et al. 1985 [100].
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Figure 5: Passive, iontophoretic and iontophoretic corrected fluxes of phenobarbital 5 hours post-
application (left panel), and passive and iontophoretic cumulative delivery of lidocaine after 6 hours
(right panel) across differentially impaired skin barriers. Iontophoretic corrected fluxes represent the
differences between iontophoretic and passive post-iontophoresis fluxes. Numerical values are given
when too small to be visualised. Data redrawn from Djabri 2009 [105] and from Sekkat et al., 2004
[103].
Figure 6: Fentanyl plasma concentrations measured during application () and removal () of a 10
cm2 transdermal system, delivering 25 µg.h-1, to 8 children aged 18-60 months. The inner and outer
boxes show the mean and the standard deviation, respectively, and the whiskers indicate the
highest and lowest concentrations at each time point. Reprinted from Paut et al., 2008 [114]; with
kind permission from John Wiley and Sons.
Figure 7: Tulobuterol serum concentrations and changes in peak expiratory flow rate (PEF) (mean ±
SE; n=6) determined following administration of a transdermal patch to 6 (4-13 y) boys; the dose was
1 mg (< 30 kg) or 2 mg ( 30 kg) depending on bodyweight; the shaded area indicates the time that
the patches were worn. Data redrawn from Iikura et al.,1995 [146].
Figure 8: Schematic diagram (left side) and top view (right side) of the heated lidocaine/tetracaine
SyneraTM/RapydanTM patch. Pictures kindly provided by Eurocept BV and reprinted from Swayer et
al., 2009 [174] with kind permission from Oxford University Press.
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